Stocks Comparison
Abbott Laboratories vs Astrazeneca: revenue, profit, margins and growth compared
Abbott Laboratories brought in $44.3B of revenue in fiscal 2025, Astrazeneca $58.7B in fiscal 2025. Revenue changed by +5.7% at Abbott Laboratories and +8.6% at Astrazeneca on the year before, so Astrazeneca grew faster. Abbott Laboratories kept 14.7% of its revenue as net profit, Astrazeneca 17.4%. Free cash flow was $7.4B at Abbott Laboratories and $11.8B at Astrazeneca.
Side by side, latest fiscal year
| ABT | AZN | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $44.3B | $58.7B |
| Revenue growth | +5.7% | +8.6% |
| Net income | $6.5B | $10.2B |
| Net margin | 14.7% | 17.4% |
| Free cash flow | $7.4B | $11.8B |
| Free cash flow margin | 16.7% | 20.0% |
| Earnings per share (diluted) | $3.72 | $6.54 |
| Cash | $8.5B | $5.7B |
| Debt | $12.9B | $29.6B |
| Price to earnings | 27.2 | n/a |
| Market value | $175.3B | $258.3B |
| Dividend yield | 2.37% | n/a |
| Rank by revenue in sector | #18 of 523 · Health care | #15 of 523 · Health care |
Over the years
Questions about Abbott Laboratories and Astrazeneca
Which is bigger by revenue, Abbott Laboratories or Astrazeneca?
Astrazeneca is bigger by revenue: $58.7B in fiscal 2025, against $44.3B for Abbott Laboratories in fiscal 2025.
Which keeps more of its revenue as profit, Abbott Laboratories or Astrazeneca?
Abbott Laboratories had a net margin of 14.7% in fiscal 2025; Astrazeneca had 17.4% in fiscal 2025.
Which grew revenue faster, Abbott Laboratories or Astrazeneca?
In their latest fiscal years revenue changed by +5.7% at Abbott Laboratories and +8.6% at Astrazeneca.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.